Literature DB >> 23500093

PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice.

M B Watson1, H Nobuta, C Abad, S K Lee, N Bala, C Zhu, F Richter, M-F Chesselet, J A Waschek.   

Abstract

Exposure to the pesticide paraquat (PQ) increases the risk of Parkinson's disease (PD), and its effect may be modulated by genetic or other environmental factors. The neuropeptide PACAP (pituitary adenylyl cyclase-activating polypeptide, Adcyap1) has been shown to enhance tyrosine hydroxylase (TH) and VMAT2 expression, protect dopaminergic (DA) neurons against the neurotoxin 6-hydroxydopamine, regulate neuronal mitochondria, and inhibit inflammation. Decreased expression of PACAP may thus interact with environmental factors such as PQ to increase the risk of PD. To mimic a low level environmental exposure to PQ, wild type (WT) and PACAP knockout (KO) mice were given a single [10 mg/kg] dose of PQ, a regimen that did not induce the loss of TH expression or DA neurons in WT mice. This treatment selectively reduced the number of TH-positive cell bodies in the substantia nigra pars compacta (SNpc) selectively in PACAP KO mice. Because inflammation is also a risk factor for PD, we performed a quantitative analysis of SNpc Iba⁺ microglia. As expected, PQ increased the number of larger microglial profiles, indicative of activation, in WT mice. Strikingly, microglial activation was already evident in PACAP KO mice in the basal state. PQ caused no further activation in these mice, although tumor necrosis factor-α gene expression was enhanced. In the periphery, PQ had no effects on the abundance of proinflammatory Th1 or Th17 cells in WT mice, but increased the numbers of anti-inflammatory regulatory T cells (Tregs). PACAP KO mice, in contrast, had elevated numbers of Th17 cells after PQ, and the induction of Tregs was impaired. The results indicate that endogenous PACAP acts to maintain the integrity of DA neurons during exposure to PQ, an action that may be linked to its ability to regulate microglia and/or other immune cells.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23500093      PMCID: PMC3637876          DOI: 10.1016/j.neuroscience.2013.03.002

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  62 in total

Review 1.  Glial cells and Parkinson's disease.

Authors:  E C Hirsch
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Alterations of T-lymphocyte populations in Parkinson disease.

Authors:  Yasuhiko Baba; Ataru Kuroiwa; Ryan J Uitti; Zbigniew K Wszolek; Tatsuo Yamada
Journal:  Parkinsonism Relat Disord       Date:  2005-09-09       Impact factor: 4.891

3.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

Authors:  Ashley D Reynolds; Rebecca Banerjee; Jianou Liu; Howard E Gendelman; R Lee Mosley
Journal:  J Leukoc Biol       Date:  2007-08-03       Impact factor: 4.962

4.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

5.  Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress.

Authors:  Sufen Yang; Jun Yang; Zhengqin Yang; Posee Chen; Alison Fraser; Wei Zhang; Hao Pang; Xi Gao; Belinda Wilson; Jau-Shyong Hong; Michelle L Block
Journal:  J Pharmacol Exp Ther       Date:  2006-08-04       Impact factor: 4.030

Review 6.  Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo.

Authors:  D Reglodi; P Kiss; A Lubics; A Tamas
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.

Authors:  Dóra Reglodi; Andrea Lubics; Andrea Tamás; Luca Szalontay; István Lengvári
Journal:  Behav Brain Res       Date:  2004-05-05       Impact factor: 3.332

8.  Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons.

Authors:  N Takei; Y Skoglösa; D Lindholm
Journal:  J Neurosci Res       Date:  1998-12-01       Impact factor: 4.164

9.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

10.  Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee.

Authors:  Taye H Hamza; Honglei Chen; Erin M Hill-Burns; Shannon L Rhodes; Jennifer Montimurro; Denise M Kay; Albert Tenesa; Victoria I Kusel; Patricia Sheehan; Muthukrishnan Eaaswarkhanth; Dora Yearout; Ali Samii; John W Roberts; Pinky Agarwal; Yvette Bordelon; Yikyung Park; Liyong Wang; Jianjun Gao; Jeffery M Vance; Kenneth S Kendler; Silviu-Alin Bacanu; William K Scott; Beate Ritz; John Nutt; Stewart A Factor; Cyrus P Zabetian; Haydeh Payami
Journal:  PLoS Genet       Date:  2011-08-18       Impact factor: 5.917

View more
  13 in total

Review 1.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

2.  Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.

Authors:  M Feher; B Gaszner; A Tamas; A L Gil-Martinez; E Fernandez-Villalba; M T Herrero; D Reglodi
Journal:  Neurotox Res       Date:  2017-12-11       Impact factor: 3.911

Review 3.  Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson's Disease.

Authors:  Dong Dong; Junxia Xie; Jun Wang
Journal:  Neurosci Bull       Date:  2019-07-08       Impact factor: 5.203

Review 4.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

5.  PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglodi; Yousef Tizabi
Journal:  Neurotox Res       Date:  2014-04-17       Impact factor: 3.911

6.  PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.

Authors:  Kai-Yvonne Shivers; Anastasia Nikolopoulou; Saima Ishaq Machlovi; Shankar Vallabhajosula; Maria E Figueiredo-Pereira
Journal:  Biochim Biophys Acta       Date:  2014-06-23

7.  Comparative protein composition of the brains of PACAP-deficient mice using mass spectrometry-based proteomic analysis.

Authors:  G Maasz; Z Pirger; D Reglodi; D Petrovics; J Schmidt; P Kiss; A Rivnyak; H Hashimoto; P Avar; E Jambor; A Tamas; B Gaszner; L Mark
Journal:  J Mol Neurosci       Date:  2014-03-19       Impact factor: 3.444

8.  Pituitary adenylate cyclase activating polypeptide modulates catecholamine storage and exocytosis in PC12 cells.

Authors:  Yan Dong; Gang Ning; Andrew G Ewing; Michael L Heien
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

9.  PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like cultures.

Authors:  Alessandro Castorina; James A Waschek; Rubina Marzagalli; Venera Cardile; Filippo Drago
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  Assessment of the Effects of MPTP and Paraquat on Dopaminergic Neurons and Microglia in the Substantia Nigra Pars Compacta of C57BL/6 Mice.

Authors:  Richard Jay Smeyne; Charles B Breckenridge; Melissa Beck; Yun Jiao; Mark T Butt; Jeffrey C Wolf; Dan Zadory; Daniel J Minnema; Nicholas C Sturgess; Kim Z Travis; Andrew R Cook; Lewis L Smith; Philip A Botham
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.